LivaNova (LivaNova) Debt-to-Equity

: 0.50 (As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

LivaNova's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $26 Mil. LivaNova's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $614 Mil. LivaNova's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $1,278 Mil. LivaNova's debt to equity for the quarter that ended in Dec. 2023 was 0.50.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for LivaNova's Debt-to-Equity or its related term are showing as below:

LIVN' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.07 Med: 0.25 Max: 0.64
Current: 0.5

During the past 13 years, the highest Debt-to-Equity Ratio of LivaNova was 0.64. The lowest was 0.07. And the median was 0.25.

LIVN's Debt-to-Equity is ranked worse than
72.71% of 711 companies
in the Medical Devices & Instruments industry
Industry Median: 0.2 vs LIVN: 0.50

LivaNova Debt-to-Equity Historical Data

The historical data trend for LivaNova's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LivaNova Annual Data

Trend

Apr14

Apr15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.29

0.64

0.22

0.48

0.50

LivaNova Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity																0.48	0.47	0.50	0.51	0.50

Competitive Comparison

For the Medical Devices subindustry, LivaNova's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LivaNova Debt-to-Equity Distribution

For the Medical Devices & Instruments industry and Healthcare sector, LivaNova's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where LivaNova's Debt-to-Equity falls into.

LivaNova Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

LivaNova's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(26.473	+	613.931)	/	1277.628
	=	0.50

LivaNova's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(26.473	+	613.931)	/	1277.628
	=	0.50

LivaNova (NAS:LIVN) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

LivaNova Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of LivaNova's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

LivaNova (LivaNova) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » LivaNova PLC (NAS:LIVN) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

LIA:Germany

Address

20 Eastbourne Terrace, London, GBR, W2 6LG

Website

https://www.livanova.com

U.K.-based LivaNova was born of a combination between Cyberonics in the U.S. and Sorin in Italy. The medical device firm is primarily focused on cardiovascular and cardiopulmonary solutions (with surgical heart valves, heart-lung machines, and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management and heart valve businesses. LivaNova derives roughly half of its revenue from the U.S. market, another 21% from Europe, and the remainder from the rest of the world.

Executives

James Christopher Barry	director	7475 LUSK BLVD, SAN DIEGO CA 92121
Damien Mcdonald	officer: COO	5 MERCHANT SQUARE, NORTH WHARF ROAD, LONDON X0 W21AY
Michael Damon Hutchinson	officer: Chief Legal Officer	2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Brooke Story	director	C/O SIGILON THERAPEUTICS, INC., 100 BINNEY STREET, SUITE 600, CAMBRIDGE MA 02142
Peter M Wilver	director
Daniel Jeffrey Moore	director	100 CYBERONICS BVLD, HOUSTON TX 77058
Alfred J Novak	director	325 NE 6TH ST, BOCA RATON FL 33432
William A Kozy	director	C/O BECTON DICKERSON & CO, 1 BECTON DR, FRANKLIN LAKES NJ 07417
Marco Dolci	officer: SVP Global Operations, R&D	VIA BENIGNO CRESPI 17, MILAN L6 20159
Todd C Schermerhorn	director	C/O C.R BARD INC, 730 CENTRAL AVE, MURRAY HILL NJ 07974
Alex Shvartsburg	officer: Interim CFO	20 EASTBOURNE TERRACE, LONDON X0 W26LG
Roy Khoury	officer: President, International	5 MERCHANT SQUARE, NORTH WHARF ROAD, LONDON X0 W21AY
Thad Allen Huston	officer: Chief Financial Officer	941 BLOOMFIELD ST, HOBOKEN NJ 07030
Seng Stacy Enxing	director	C/O HILL-ROM HOLDINGS, INC., SUITE 4100 180 NORTH STETSON AVENUE, CHICAGO IL 60601
Trui Hebbelinck	officer: Chief Human Resources Officer	20 EASTBOURNE TERRACE, LONDON X0 W2 6LG